NCT05621590View on ClinicalTrials.gov

MLC901 in Hypoxic-ischemic Brain Injury Patients; A Double-blind, Randomized Placebo-controlled Trial

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 10, 2020

Primary Completion Date

August 12, 2022

Study Completion Date

August 12, 2022

Conditions
Hypoxic Ischaemic Encephalopathy Due to Cardiac Arrest
Interventions
DRUG

MLC 901

MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components

DRUG

Placebo

placebo capsules filled with stevia sweetened powder

Trial Locations (1)

Unknown

Shahid Beheshti University of Medical Sciences, Shohada Hospital, Tehran

All Listed Sponsors
lead

Shahid Beheshti University of Medical Sciences

OTHER

NCT05621590 - MLC901 in Hypoxic-ischemic Brain Injury Patients; A Double-blind, Randomized Placebo-controlled Trial | Biotech Hunter | Biotech Hunter